509 related articles for article (PubMed ID: 17849041)
1. Coagulation factor V and thrombophilia: background and mechanisms.
Segers K; Dahlbäck B; Nicolaes GA
Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
[TBL] [Abstract][Full Text] [Related]
2. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Dahlbäck B
Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
[TBL] [Abstract][Full Text] [Related]
3. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
Dahlbck B
J Intern Med Suppl; 1997; 740():1-8. PubMed ID: 9350175
[TBL] [Abstract][Full Text] [Related]
4. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
5. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
De Stefano V; Leone G
Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
[TBL] [Abstract][Full Text] [Related]
6. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
Dahlbäck B
Thromb Haemost; 1995 Jul; 74(1):139-48. PubMed ID: 8578447
[TBL] [Abstract][Full Text] [Related]
7. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
Dahlbäck B
Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
[TBL] [Abstract][Full Text] [Related]
8. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
[TBL] [Abstract][Full Text] [Related]
9. [The significance of APC resistance (activated protein C) for clinical practice].
Lämmle B; Demarmels Biasiutti F; Wuillemin WA; Stucki B; Furlan M
Praxis (Bern 1994); 1997 Jan; 86(5):154-61. PubMed ID: 9064734
[TBL] [Abstract][Full Text] [Related]
10. Activated protein C resistance in anterior ischaemic optic neuropathy.
Nagy V; Facsko A; Takacs L; Balazs E; Berta A; Balogh I; Edes I; Czuriga I; Pfliegler G
Acta Ophthalmol Scand; 2004 Apr; 82(2):140-3. PubMed ID: 15043529
[TBL] [Abstract][Full Text] [Related]
11. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
Dahlbäck B
Thromb Haemost; 1997 Jul; 78(1):483-8. PubMed ID: 9198201
[TBL] [Abstract][Full Text] [Related]
12. Early days of APC resistance and FV Leiden.
Dahlbäck B
Hamostaseologie; 2008; 28(3):103-9. PubMed ID: 18521487
[TBL] [Abstract][Full Text] [Related]
13. Congenital and acquired activated protein C resistance.
Nicolaes GA; Dahlbäck B
Semin Vasc Med; 2003 Feb; 3(1):33-46. PubMed ID: 15199491
[TBL] [Abstract][Full Text] [Related]
14. [National evaluation of the diagnosis of activated protein C resistance].
Montiel-Manzano G; de la Peña-Díaz A; Majluf-Cruz A; Cesarman-Maus G; Corona-de la Peña N; Cruz-Cruz D; Gaminio E; Martínez-Murillo C; Mayagoitia T; Miranda-Peralta E; Poblete T; Quintana-Martínez S; Ramírez R; Razo D; Ruiz de Chávez-Ochoa A; Reyes-Núñez VA; Salazar R; Vicencio-Santiago GV; Villa R
Rev Invest Clin; 2003; 55(3):358-69. PubMed ID: 14515684
[TBL] [Abstract][Full Text] [Related]
15. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
17. The discovery of activated protein C resistance.
Dahlbäck B
J Thromb Haemost; 2003 Jan; 1(1):3-9. PubMed ID: 12871530
[TBL] [Abstract][Full Text] [Related]
18. Activated protein C resistance: molecular mechanisms.
Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
[TBL] [Abstract][Full Text] [Related]
19. Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review.
Jespersen J
Eur J Contracept Reprod Health Care; 1996; 1(1):3-11. PubMed ID: 9678132
[TBL] [Abstract][Full Text] [Related]
20. The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
Tosetto A; Castaman G; Cappellari A; Rodeghiero F
Thromb Haemost; 2000 Nov; 84(5):811-4. PubMed ID: 11127861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
